Efficacy of lanreotide 120mg primary therapy on tumour shrinkage and ophthalmologic symptoms in acromegaly after 1 month

• Published in: Clinical endocrinology (Oxford) 2022-07, Vol.97 (1), p.52-63
• Main Authors: Hamza Benderradji, Vernotte, Elise, Gustave Soto Ares, Woillez, Jean Philippe, Jannin, Arnaud, Perbet, Romain, Mélodie‐Anne Karnoub, Soudan, Benoît, Assaker, Richard, Buée, Luc, Prevot, Vincent, Claude‐Alain Maurage, Pigny, Pascal, Marie‐Christine Vantyghem, Merlen, Emilie, Cortet, Christine
• Format: Article
• Language: English
• Subjects: Acromegaly; Compression; Growth hormones; Insulin-like growth factors; Magnetic resonance imaging; Optic chiasm; Patients; Pituitary; Somatostatin; Tumors; Visual field
• ISSN: 0300-0664; 1365-2265
• DOI: 10.1111/cen.14748

IntroductionFew studies have attempted to evaluate the early efficacy of first‐generation somatostatin analogues in somatotroph macroadenomas.ObjectiveTo investigate the short‐term efficacy of primary therapy with lanreotide 120 mg at 1 and 3 months on tumour shrinkage and ophthalmologic symptoms in newly diagnosed patients with acromegaly.Design and PatientsThis single‐centre retrospective study included 21 patients with de novo acromegaly resulting from pituitary macroadenoma, with optic chiasm compression (Grade ≤ 2) and/or cavernous sinus invasion, treated with a monthly injection of lanreotide 120 mg. Clinical, hormonal, ophthalmologic and magnetic resonance imaging scan evaluations were conducted after the first and the third months of treatment.ResultsTumour volume reduction was more pronounced at 1 month; mean volume change: −31.4 ± 19.5%, p